Virologic response and resistance to adefovir in patients with chronic hepatitis B

Journal of Hepatology

Volumn 44, Issue 2, 2006, Pages 283-290

  Fung, Scott K ^a   Chae, Hee Bok ^a   Fontana, Robert J ^a   Conjeevaram, Hari ^a   Marrero, Jorge ^a   Oberhelman, Kelly ^a   Hussain, Munira ^a   Lok, Anna S F ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adefovir; Antiviral resistance; Hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MALE; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 30344449469     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.10.018     Document Type: Article

References (29)

1. P. Marcellin, T.T. Chang, S.G. Lim, M. Tong, W. Sievert, and M. Schiffman Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
2. M. Peters, H.W. Hann, P. Martin, E.J. Heathcote, P. Buggisch, and R. Rubin Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
3. S. Hadziyannis, N. Tassopoulos, J. Heathcote, T.-T. Chang, G. Kitis, and M. Rizzetto Adefovir dipivoxil for the treatment of hepatitis B e-antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
4. R.P. Perrillo, H.W. Hann, D. Mutimer, B. Willems, N. Leung, and W.M. Lee Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 2004 81 90
5. E. Schiff, C.L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, and M. Colombo Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 2003 1419 1427
6. S. Locarnini, X. Qi, S. Arterburn, A. Snow, C.L. Brosgart, and G. Currie Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) (abstract) J Hepatol 42 Suppl. 2 2005 A36
7. C.E. Westland, H. Yang, W.E. Delaney, C.S. Gibbs, M.D. Miller, and M. Wulfsohn Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B Hepatology 38 2003 96 103
8. A.S.F. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
9. P. Angus, R. Vaughan, S. Xiong, H. Yang, W.E. Delaney, and C.S. Gibbs Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292 297
10. J.P. Villeneuve, D. Durantel, S. Durantel, C.E. Westland, S. Xiong, and C. Brosgart Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient J Hepatol 39 2003 1085 1089
11. A. Bartholomeusz, S. Locarnini, A. Ayres, G. Thompson, V. Sozzi, and P. Angus Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations (abstract) Hepatology 40 2004 A185
12. S. Locarnini, T. Shaw, T. Sozzi, R. Edwards, G. Currie, and C. Brosgart HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro (abstract) Hepatology 40 2004 182A
13. H. Yang, X. Qi, K. Das, E. Arnold, C.E. Westland, and W.E. Delaney In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase (abstract) J Hepatol 40 2004 A383
14. S.K. Fung, P. Andreone, S.H. Han, K.R. Reddy, A. Regev, and E. Keeffe Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation J Hepatol 43 2005 937 943
15. A.S.F. Lok, F. Zoulim, S. Locarnini, A. Mangia, G. Niro, and H. Decraemer Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay J Clin Microbiol 40 2002 3729 3734
16. S. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673 2681
17. C.L. Lai, J. Dienstag, E. Schiff, N. Leung, M. Atkins, and C. Hunt Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696
18. M.F. Yuen, E. Sablon, C.K. Hui, H.J. Yuan, H. Decraemer, and C.L. Lai Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791
19. C.L. Lai, N.W. Leung, E.K. Teo, M. Tong, F. Wong, and H.W. Hann A one-year trial of telbivudine, lamivudine, and the combination in patients with HBeAg-positive chronic hepatitis B Gastroenterology 129 2005 528 536
20. X. Qi, A. Snow, V. Thibault, Y. Zhu, M. Curtis, and S. Hadziyannis Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy (abstract) J Hepatol 40 2004 A57
21. S. Durantel, B. Werle, D. Durantel, C. Pichoud, G. Currie, and S. Xiong Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B (abstract) Hepatology 40 2004 A1132
22. T. Berg, and F. van Bommel Reactivation of viral replication after replacement of tenofovir by adefovir Hepatology 42 2005 239 240
23. F. van Bommel, T. Wunsche, S. Mauss, P. Reinke, A. Bergk, and D. Schurmann Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 2004 1421 1425
24. N. Ogata, K. Fujii, S. Takigawa, M. Nomoto, T. Ichida, and H. Asakura Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B J Med Virol 59 1999 270 276
25. Y.F. Liaw, R.N. Chien, and C.T. Yeh No benefit to continue lamivudine after the emergence of YMDD mutations Antivir Ther 9 2004 145 148
26. A. Snow, V. Thibault, X. Qi, Y. Zhu, C.E. Westland, and S. Arterburn Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-reistant HBV (abstract) Gastroenterology 128 2005 M945
27. C.E. Westland, W.E. Delaney, H. Yang, S.S. Chen, P. Marcellin, and S. Hadziyannis Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil Gastroenterology 125 2003 107 116
28. B. Zollner, J. Petersen, E. Puchhammer-Stockl, J. Kletzmayr, M. Sterneck, and L. Fischer Viral features of lamivudine resistant hepatitis B genotypes A and D Hepatology 39 2004 42 50
29. M.N. Brunelle, A.C. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-Durantel, and J.P. Villeneuve Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir Hepatology 41 2005 1391 1398